PMID- 35173732
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220328
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Structural Basis for Unusual TCR CDR3beta Usage Against an Immunodominant HIV-1 Gag 
      Protein Peptide Restricted to an HLA-B*81:01 Molecule.
PG  - 822210
LID - 10.3389/fimmu.2022.822210 [doi]
LID - 822210
AB  - In HIV infection, some closely associated human leukocyte antigen (HLA) alleles 
      are correlated with distinct clinical outcomes although presenting the same HIV 
      epitopes. The mechanism that underpins this observation is still unknown, but may 
      be due to the essential features of HLA alleles or T cell receptors (TCR). In 
      this study, we investigate how T18A TCR, which is beneficial for a long-term 
      control of HIV in clinic, recognizes immunodominant Gag epitope TL9 
      (TPQDLTML180-188) from HIV in the context of the antigen presenting molecule 
      HLA-B*81:01. We found that T18A TCR exhibits differential recognition for TL9 
      restricted by HLA-B*81:01. Furthermore, via structural and biophysical 
      approaches, we observed that TL9 complexes with HLA-B*81:01 undergoes no 
      conformational change after TCR engagement. Remarkably, the CDR3beta in T18A 
      complexes does not contact with TL9 at all but with intensive contacts to 
      HLA-B*81:01. The binding kinetic data of T18A TCR revealed that this TCR can 
      recognize TL9 epitope and several mutant versions, which might explain the 
      correlation of T18A TCR with better clinic outcomes despite the relative high 
      mutation rate of HIV. Collectively, we provided a portrait of how CD8(+) T cells 
      engage in HIV-mediated T cell response.
CI  - Copyright (c) 2022 Liu, Lei, San, Yang, Paek, Xia, Chen and Yin.
FAU - Liu, Yang
AU  - Liu Y
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
FAU - Lei, Jun
AU  - Lei J
AD  - Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, 
      China.
FAU - San, Dan
AU  - San D
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
FAU - Yang, Yi
AU  - Yang Y
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
FAU - Paek, Chonil
AU  - Paek C
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
FAU - Xia, Zixiong
AU  - Xia Z
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
FAU - Chen, Yongshun
AU  - Chen Y
AD  - Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, 
      China.
FAU - Yin, Lei
AU  - Yin L
AD  - State Key Laboratory of Virology, College of Life Sciences, Wuhan University, 
      Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220131
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-B Antigens)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (gag Gene Products, Human Immunodeficiency Virus)
SB  - IM
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - HIV-1/*metabolism
MH  - HLA-B Antigens/*immunology
MH  - Humans
MH  - Immunodominant Epitopes/immunology
MH  - Mutation/*genetics
MH  - Receptors, Antigen, T-Cell/*metabolism
MH  - gag Gene Products, Human Immunodeficiency Virus/chemistry/*genetics
PMC - PMC8841528
OTO - NOTNLM
OT  - CD8+ T cells
OT  - HIV
OT  - HLA
OT  - T cell receptor
OT  - antigen presentation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/18 06:00
MHDA- 2022/03/29 06:00
PMCR- 2022/01/01
CRDT- 2022/02/17 05:35
PHST- 2021/11/25 00:00 [received]
PHST- 2022/01/12 00:00 [accepted]
PHST- 2022/02/17 05:35 [entrez]
PHST- 2022/02/18 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.822210 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jan 31;13:822210. doi: 10.3389/fimmu.2022.822210. eCollection 
      2022.